Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab

Itô, Tatsuya; Sato, Hiroki; Tsujikawa, Takahiro; Hirai, Hideaki; Okamoto, Isaku; Miyake, Keitaro; Nagao, Toshitaka; Tsukahara, Kiyoaki

doi:10.1016/j.anl.2020.02.014

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with metastatic HNSCC treated with ICIs may experience mixed responses, wherein after ICIs administration tumor shrinkage and progression are observed in different lesions. In these patients, RT or surgery for progressive lesions improved survival 19,20 . As more ICIs are used for systemic therapy, the number of patients with M1 disease who develop mixed response would increase.…”

Section: Discussionmentioning

confidence: 99%

“…In these patients, RT or surgery for progressive lesions improved survival. 19,20 As more ICIs are used for systemic therapy, the number of patients with M1 disease who develop mixed response would increase. For these patients with lesions that remain localizing after systemic chemotherapy, RT or surgery can be a potential treatment option.…”

Section: Rt or Surgery After Icis Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Outcome in Head and Neck Cancer With Distant Metastasis at Initial Diagnosis

Omata,

Ueki,

Takahashi

et al. 2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectiveRecurrent/metastatic head and neck squamous cell carcinoma (HNSCC) treatment has changed dramatically with the introduction of immune checkpoint inhibitors (ICIs). However, there are few reports of treatment outcomes on HNSCC with distant metastasis (M1) at initial diagnosis, and its treatment strategy has not been standardized. We aimed to analyze the treatment outcome and prognostic factors of patients with HNSCC with initial M1 disease.MethodsIn this multi‐institutional retrospective study, 98 patients with HNSCC were initially diagnosed with M1 disease between 2007 and 2021. The patients were divided into the non‐palliative (received any systemic chemotherapy, n = 60) and palliative (did not receive systemic chemotherapy, n = 38) groups. Overall survival (OS) was compared between the groups. In the non‐palliative group, predictors of OS were explored based on patient characteristics and treatment details.ResultsThe median OS in the non‐palliative group was 15 months (95% confidence interval [CI], 10–20), which was significantly longer than that in the palliative group (3 months, 95% CI, 2–5) (p < 0.001). Multivariate analysis revealed that administration of locoregional radiation therapy (RT) (hazard ratio [HR] 0.407 [95% CI 0.197–0.844]; p = 0.016), ICIs (HR 0.216 [95% CI 0.088–0.532]; p < 0.001) and RT/surgery for distant metastasis (HR 0.373 [95% CI 0.150–0.932]; p = 0.034) were the independent prognostic factors of OS.ConclusionAn intensive treatment strategy combining systemic therapy using ICIs with RT/surgery for locoregional or distant metastasis may yield a survival benefit for patients with HNSCC with M1 disease.Level of Evidence4 Laryngoscope, 2023

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Rt or Surgery After Icis Treatmentmentioning

confidence: 99%